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P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITORValue of CT in Patients Undergoing
Self-Expandable TAVR to Assess Outcomes
of Concomitant Mitral RegurgitationCurrent guidelines on valvular heart disease recom-
mend double valve replacement when signiﬁcant
aortic stenosis and mitral regurgitation (MR) occur
simultaneously (1,2). Given the higher risk of
combined mitro-aortic surgery, transcatheter aortic
valve replacement (TAVR) has emerged as a good
alternative, with a constant improvement (up to 60%)
in MR degree after TAVR (3), especially if the MR was
of functional etiology. However, the deﬁnition of
functional MR is challenging in patients with TAVR.
The value of multidetector computed tomography
(MDCT) in the assessment of mitral valves in this
scenario is unknown (4); therefore, our aims were to:
1) conﬁrm the feasibility of mitral valve character-
ization with MDCT in the context of TAVR; and 2)
determine MDCT predictors of MR improvement.
One hundred consecutive patients diagnosed with
severe aortic stenosis were treated by transfemoral
TAVR with the CoreValve system (Medtronic Inc.,
Minneapolis, Minnesota) in our institution. Six pa-
tients with previousmitralmechanical prosthesis were
excluded from the analysis. Patients were classiﬁed,
according to their echocardiographic baseline degree
of MR, in “low-degreeMR” for grades 0 and 1 (effective
regurgitant oriﬁce [ERO] <2 cm2; i.e., none or mild) or
“high-degree MR” for grades 2, 3, and 4 (ERO $2 cm2;
i.e., moderate for 2 and 3 and severe for 4) (1,2). We
considered an improvement in MR to be signiﬁcant
when degree of MR changed from high to low.
All patients underwent complete serial trans-
thoracic echocardiography. Ofﬂine analysis was per-
formed by 3 experienced echocardiographers (A.R.,
J.R.A., and J.A.S.R.) blinded to further data. Trans-
esophageal echocardiography was only performed
when clinically indicated (in 10 patients with ERO$0.3
cm2 and unclear functional/organic etiology).
MDCT examinations were performed with a 64-
row MDCT scanner (LightSpeed VCR, GE Healthcare,
Little Chalfont, United Kingdom) during inspiratory
breath-hold using contrast (iohexol 350 mg/ml)
in a nongated fashion. MDCT was used to measure
mitral annulus diameter. Location and degree of
calciﬁcation of the mitral annulus and leaﬂets were
semi-quantitatively graded as described in Figure 1.Analysis of MDCT images was carried out by an
expert in cardiac imaging (A.R.).
Mitral annulus size measured was related to MR
improvement with a high echocardiographic/MDCT
correlation (0.996; 95% conﬁdence interval [CI]: 0.993
to 0.998). The cutoff value that best predicted MR
improvement was 35.95 mm. The echocardiographic
degree of calciﬁcation affecting the mitral valve
structures did not show signiﬁcant differences. In
contrast, the presence of any degree of leaﬂet calciﬁ-
cation ($1) by MDCT was an independent predictor of
lack of MR improvement (76.5% vs. 23.1%, OR: 6.8
[95% CI: 1.3 to 37.0], p ¼ 0.026), as well as mitral
annulus diameter (34.7  3.5 mm vs. 39.7  3.8 mm,
OR: 13.5 [95% CI: 2.5 to 76.9], p ¼ 0.003). In addition,
the detection of calcium at the mitro-aortic junction
by MDCT, related to higher likeliness of left bundle
branch block, determined a higher risk of MR persis-
tence. On the contrary, calciﬁcation of the mitral
annulus was not associated with the evolution of MR.
MDCT is particularly useful in patients undergoing
TAVR (1,2) to evaluate the aorto-iliac axis and
for providing relevant information on mitral valve
to predict long-term MR improvement after TAVR.
It is not clear why calciﬁcation of some of the
mitral apparatus elements is associated with MR
improvement but not calciﬁcation of other parts. We
believe that mitral leaﬂet stiffness provoked by cal-
cium is an important determinant of MR and
its remains. These ﬁndings will have to be clariﬁed in
future prospective research due to the limited number
of patients, which restricted multivariate analysis.
In conclusion, MDCT analysis of the mitral anat-
omy in patients undergoing TAVR determined the
absence of calciﬁcation of mitral leaﬂets and lower
annulus diameter as main predictors of MR im-
provement. The extended use of MDCT in TAVR
candidates and the simplicity of these measurements
may be helpful in the decision-making process for
patients with mitro-aortic disease given the current
controversy about their management.Ignacio J. Amat-Santos, MD*
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FIGURE 1 Different Degrees and Location of Calciﬁcation of the Mitral Valve
Mitral valve assessed by multidetector computed tomography (MDCT) (top images of each panel) and echocardiography (bottom images of each panel) in long-
and short-axis views. (A) Absence of calciﬁcation. (B) High degree of annulus calciﬁcation (short arrows), without leaﬂet involvement. (C) High degree of annulus
calciﬁcation (short arrows) and moderate calciﬁcation of the leaﬂets (long arrows).
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Using Echocardiographic DataThree-dimensional (3D) printing has steadily gained
traction as a clinical tool. Current applications
include developing patient-speciﬁc implants, pros-
theses, and realistic anatomic models for surgical
